Background: Oral administration of magnesium and boron might have a beneficial
| INTRODUCTION
Trigeminal-mediated headshaking, formerly known as idiopathic headshaking, is caused by a low threshold of firing of the trigeminal nerve. [1] [2] [3] Affected horses demonstrate abnormal behavior with headshaking such as sudden jerking of the head with a downward then upward motion, rubbing the nose on their thoracic limbs or objects, lip movements, and excessive snorting, noted mostly during exercise. 1, 4 The clinical signs of headshaking are suspected to result from neuropathic pain, considering the low threshold for firing of the trigeminal nerve in affected horses. 2 The horse's behavior suggests neuropathic pain that is manifested as an itching, burning, tingling, or electric-like sensation. 4, 5 In most cases, clinical manifestation is seasonal with worsening of signs during spring and summer months, and geldings are overrepresented. 4, [6] [7] [8] [9] Various treatments have been attempted to alleviate the signs including physical devices such as face masks with ultraviolet light protection, nose nets, nutritional supplements, drug treatment, including administration of antidepressants, channel blockers, antihistamines or corticosteroids, neuromodulation, and caudal compression of the infraorbital nerve, among others. 1, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] However, the results have been variable. Unsuccessful management of this condition is associated with uncontrollable clinical signs often leading to poor performance, wastage, and, in severe cases, euthanasia, representing an equine welfare issue.
An owner-based survey indicated that magnesium supplementation is perceived to decrease headshaking behavior in 40% of horses affected with trigeminal-mediated headshaking. 1, 19 Owner-based surveys have limitations such as the interpretation of signs and response to treatment, familiarity with the disorder, confusion with other disorders that might cause headshaking, and placebo effects. Some horses affected with trigeminal-mediated headshaking have ionized magnesium concentrations below the reference range (mean of 0.44 ± 0.05; reference range 0.47-0.70). 20 Administration of intravenous magnesium sulfate infusion given to horses affected with trigeminal-mediated headshaking significantly decreased headshaking behavior by 29%. 21 Boron increases blood ionized magnesium concentrations. 22 Therefore, this study sought to evaluate the effects of dietary supplementation of magnesium and boron on headshaking behavior in horses.
We hypothesized that magnesium supplementation with or without boron would decrease headshaking behavior in horses affected with trigeminal-mediated headshaking. We also hypothesized that boron would enhance absorption of magnesium, further increasing blood concentrations of ionized magnesium and further decrease headshaking behavior.
| MATERIALS AND METHODS

| Animals
Twelve male castrated horses, Quarter Horse breeds (n = 8) and Thoroughbred (n = 4), aged 7 to 16 years, weighing between 465 and 636 kg were enrolled in the study. Six horses were diagnosed with trigeminal-mediated headshaking and 6 healthy horses matched for age and breed were selected as controls. 
| Experimental design
The study was a randomized, controlled crossover experimental design, where each horse served as its own control. 
| Sample collection
Blood samples (10 mL in evacuated tube containing heparin as anticoagulant and 1.5 mL in heparinized syringes) were collected by venipuncture from the right jugular vein before initiation of dietary supplementation (baseline) and after completion of a week of dietary supplementation. All samples were collected before exercise and samples were placed on ice immediately and analyzed within 2 hours. 3 | RESULTS
| Blood analysis
| Blood results
| Statistical modeling
There was a significant increase in Mg Significant differences than treatment PF for all horses. c Significant differences than treatment M for all horses.
P < .05 was considered significant difference on tMg (P < .001) between PF, M, and MB treatments compared to H treatment. There was a significant difference on tMg (P < .01) between M and MB treatments compared to PF treatment.
There was a significant difference on tMg (P = . There was a significant increase in Ca 2+ with all treatments (PF, M, and MB) when compared to baseline diet H (Figure 3 , P < .001).
| Effect of baseline hay diet on blood variables
At baseline (H), all blood variables were within reference range except for SBE that were uniformly above reference range (mean, 6.9 ± 0.8 mmol/L for controls; mean, 6.9 ± 1.3 mmol/L for headshakers; Table 1 ), Mg 2+ (mean, 0.45 ± 0.03 mmol/L for controls; mean, 0.46 ± 0.03 mmol/L for headshakers; Table 1 ), and SID (mean, 47.6 ± 1.7 mmol/L for controls; mean, 47.6 ± 2.5 mmol/L for headshakers; Table 2 ).
| Effect of PF on blood variables
Treatment PF caused a decrease in SBE from baseline (H) but remained above the reference range (mean, 4.3 ± 1.2 mmol/L for controls; mean, 4.1 ± 0.9 mmol/L for headshakers; Table 1 ). There was a decrease in Na + in headshaker horses only (mean, 134 ± 1.1 mmol/L; Table 1 ). There was an increase in Cl − to above reference range (mean, 103 ± 1.6 mmol/L for controls; mean, 103 ± 1.0 mmol/L for headshakers; Table 1 ). There was a decrease in AG to below reference range for all horses (mean, 7.5 ± 1.0 mmol/L for controls; mean, 6.9 ± 0.6 mmol/L for headshakers; Table 2 ). There was an increase in Ca 2+ above reference range (mean, 1.62 ± 0.05 for controls; mean, 1.64 ± 0.06 for headshakers; Table 1 ).
| Effect of magnesium supplement on blood variables
Treatment M caused a decrease in SBE from baseline (H) but was still above reference range (mean, 3.8 ± 1.7 mmol/L for controls; mean, 5.4 ± 1.9 mmol/L for headshakers; Table 1 ). There was a decrease in Na + in headshaker horses only (mean, 134 ± 1.0 mmol/L; Table 1 ).
There was an increase in Cl − to above reference range in control horses only (mean, 103 ± 1.5 mmol/L for controls; Table 1 ). There was a decrease in AG to below reference range for all horses (mean, 7.7 ± 0.6 mmol/L for controls; mean, 6.2 ± 1.1 mmol/L for headshakers; Table 2 ). There was an increase in Ca 2+ above reference range (mean, 1.64 ± 0.03 for controls; mean, 1.64 ± 0.07 for headshakers; Table 1 ).
| Effect of magnesium and boron supplement on blood variables
Treatment MB caused a decrease in SBE from baseline (H) but was still above reference range (mean, 4.8 ± 1.2 mmol/L for controls; mean, 4.2 ± 0.3 mmol/L for headshakers; Table 1 ). There was a horses. c Significant differences than treatment M for all horses.
P < .05 was considered significant decrease in Na + for headshaker horses only (mean, 134 ± 0.8 mmol/L; Table 1 ). There was an increase in Cl − to above reference range (mean, 103 ± 1.9 mmol/L for controls; mean, 103 ± 2.7 mmol/L for headshakers; Table 1 ). There was a decrease in SID for headshaker horses only (mean, 37.3 ± 2.3 mmol/L; Table 2 ). There was a decrease in AG to below reference range for all horses (mean, 7.5 ± 0.8 mmol/L for controls; mean, 6.2 ± 1.3 mmol/L for headshakers; Table 2 ). There was an increase in Ca 2+ to above reference range (mean, 1.61 ± 0.05 mmol/L for controls; mean, 1.62 ± 0.07 mmol/L for headshakers; Table 1 ).
| Behavior results
Control horses did not show signs of headshaking behavior and were not included in the data that follows. In addition to headshaking, other 
| Treatment PF as control
The model was run with PF treatment as the control value. There was an effect of H treatment with 1.78 times the risk of headshaking as compared to PF treatment, resulting in a 79% increase in median headshakes/minute (IRR, 1.789; CI, 1.39, 2.30; P < .001; Table 3 ).
There was an effect of MB treatment with 0.64 times the risk of headshaking compared to PF treatment, resulting in a 36% decrease in median headshakes/minute (IRR, 0.642; CI, 0.47, 0.88; P = .007; Table 3 ). There were no significant differences between M treatment compared to PF treatment.
| Treatment M as control
The model was run with M treatment as the control value. There was an effect of H treatment with 2.09 times the risk of headshaking compared to M treatment, resulting in a 2-fold increase in median T A B L E 2 Calculated SID and AG. Calculated changes in blood variables after diet treatments H, PF, M, and MB Abbreviations: H, hay only, no supplement; M, pelleted feed combination, hay, and magnesium supplementation; MB, pelleted feed combination, hay, and magnesium-boron supplementation; PF, pelleted feed combination and hay only. Numbers in bold indicated values above or below the reference range.
F I G U R E 4
Overall effect of treatment on the headshakes per minute at different gaits. The mean and SEM median headshakes per minute for all 6 affected horses. Black circle = treatment H (hay only), dark gray square = treatment PF (pelleted feed combination), gray triangle = treatment M (PF plus magnesium supplement), light gray diamond = treatment MB (PF plus magnesium and boron supplements)
headshakes/minute (IRR, 2.098; CI, 1.61, 2.73; P < .001; Table 3 ).
There were no significant differences between PF and MB treatments compared to M treatment.
| Treatment MB as control
The model was run with MB treatment as the control value. There was an effect of H treatment with 2.79 times the risk of headshaking compared to MB treatment, resulting in an almost 3-fold increase in median headshakes/minute (IRR, 2.786; CI, 2.08, 3.73; P < .001; Table 3 ).
There was an effect of PF treatment with 1.56 times the risk of headshaking compared to MB treatment, resulting in a 56% increase in median headshakes/minute (IRR, 1.557; CI, 1.13, 2.15; P = .007; Table 3 ). There was not a significant difference between M treatment and MB treatment.
| Agreement between evaluators
Spearman's correlation was run to assess interobserver variability of 3 evaluators. There was strong agreement between observer 1 and 2 (r s = 0.95; P < .0001), observer 1 and 3 (r s = 0.93; P < .0001), and observer 2 and 3 (r s = 0.94; P < .0001).
| DISCUSSION
This study revealed a reduction in headshaking behavior with diets providing magnesium supplementation. Horses receiving diet with PF, M, and MB had significant reductions in headshaking behavior.
Despite the fact that there was great variability in the severity of headshaking behavior between horses and variability of the same horses on different days, the IRR analysis takes into account these variables and provides a way to look at the effect of supplementation in headshaking behavior. Combined magnesium-boron supplementation induced the highest IRR reduction (64%) in headshaking behavior when compared to hay diet only. Similarly, magnesium-boron supplementation had the greatest IRR reduction (36%) in headshaking behavior when compared to a diet containing pelleted feed. The most severely affected horses had the most benefit to supplementation providing magnesium (data not shown). As previously shown, as exercise intensity increased headshaking behavior also increased. Abbreviations: CI, confidence interval; M, pelleted feed combination, hay, and magnesium supplementation; MB, pelleted feed combination, hay, and magnesium-boron supplementation; PF, pelleted feed combination and hay only. P < .05 was considered significant.
excitation-secretion coupling. 25 Magnesium also acts on the neuromuscular blockade by inhibiting calcium channels. 26 The requirement for magnesium in horses is 13 mg/kg BW and for an average 500 kg horse, the requirement would be 6.5 g of magnesium a day. 27 Water would provide 510 mg of magnesium for a horse drinking an average of 7.5 gal per day (standard range is 5-10 gal per day). 28 Hay provided an average of 10 g of magnesium and with 45% average bioavailability (ie, approximately 4.5 g of magnesium). The baseline diet was calculated to provide 10 mg/kg magnesium for our group of horses.
The pelleted feed selected for this study provided 842 mg of magnesium based on the 255 g serving size per horse. This pelleted feed was selected for palatability and its ability to help mask the flavors of the added supplements and more specifically the boron supplement which had a bitter taste. The addition of this specific pelleted feed in combination with applesauce and canola oil was not expected to greatly increase Mg 2+ nor affect headshaking behavior; however, it did in this group of horses. Factors such as the canola oil and applesauce might have provided conditions to improve magnesium absorption. These effects were not addressed in this study, but further studies in a larger population of diseased horses could show insight into this intriguing finding. Also, it is unknown if this finding (increase magnesium) would be observed with other types of concentrates or pelleted feed.
The mechanism by which magnesium supplementation in the form of magnesium alone or magnesium in combination with boron resulted in significant reduction in headshaking behavior is not completely understood. Treatment with magnesium in combination with boron induced the greatest reduction (64% decrease in headshakes/minute) in headshaking behavior. This could be because of boron's ability to increase magnesium concentrations in the blood. 22 Magnesium can then provide its physiological channel blocking effects on N-methyl-D-aspartate (NMDA) receptors and reduce ion currents.
29-32
The NMDA receptors affect trigeminal neurons at the trigeminal subnucleus caudalis (the orofacial nocioceptive processing center) in rats. 33 Boron can also affect neurotransmitters because of its ability to form complexes with sugars. 34 When boric acid forms ester complexes with ribose, which is a part of adenosine, boric acid will noncompetitively inhibit adenosine diphosophate ribosyl cyclase (ADP-ribosyl cyclase). 35 This slows the production of cyclic ADP-ribose (cADPR) which in turn slows down mobilization of Ca
2+
. Furthermore, calcium might be involved in trigeminal neuropathic pain, but the exact mechanism is unknown. 36 The main limitations of the current study included the small num- Seasonality has a potential effect on severity of headshaking however this study was performed within 6 weeks at the peak of headshaking behavior in our group of horses as an attempt to minimize the effect that seasonality could have played. Nerve conduction velocity of the trigeminal complex before and after dietary supplementation would have been a more objective manner to assess the effects of magnesium supplementation on the threshold for nerve firing. However, this required general anesthesia and was not performed.
Although the overall decrease in headshaking behavior in this group of 6 horses might not reflect the effects on the headshaking population at large, this is a promising therapeutic option that should be investigated in a broader population of horses affected with trigeminal-mediated headshaking. Although magnesium supplementation did not completely alleviate all headshaking behavior, a reduction might improve the horse's quality of life and performance, make a horse rideable or manageable, and avoid euthanasia.
In conclusion, magnesium supplementation (PF, magnesium alone, and magnesium in combination with boron) had effects on reducing headshaking behavior in this small group of horses under the conditions of the study. Magnesium in combination with boron appeared to transiently reduce the severity of headshaking to a greater extent.
Magnesium supplementation could be considered, especially if ionized magnesium is low as was found in the horses with headshaking in this study. Supplementation with magnesium could be considered as an adjunct to other treatment attempts for the management of trigeminal-mediated headshaking.
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